This site is intended for healthcare professionals only
DiabetesontheNet Logo
×
This promotional webinar has been developed and funded by Lilly. Lilly products will be discussed at this online event and prescribing information can be found on the platform. OmniaMed Communications has provided editorial, marketing and logistical support. Lilly is a registered trademark of Eli Lilly and Company © 2021 Eli Lilly and Company. All rights reserved.

Prescribing information and adverse event reporting information for Trulicity® (dulaglutide) can be accessed by clicking here
For more information about Trulicity® (dulaglutide) please visit: www.lillydiabetes.co.uk (UK only)

An evidence-informed yet person-centred approach to the management of cardiovascular risk in type 2 diabetes

Trulicity® (dulaglutide) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.

  • In addition to other medicinal products for the treatment of diabetes

Adverse event reporting information can be found at the bottom of the page.

ABOUT THE WEBINAR

An evidence-informed yet person-centred approach to the management of cardiovascular risk in type 2 diabetes

Providing optimal care for people with type 2 diabetes needs careful consideration of not only their glycaemic level, but also their cardiovascular risk. Pharmacological options for the management of type 2 diabetes are now available that are not only effective at lowering blood glucose levels but can also offer benefits in primary or secondary prevention of cardiovascular events. Which patients could benefit from treatment with such options, and how can the right treatment be matched to the right patient?

 

 

Join our speakers Dr Shahzada Khan (Chair), Dr Ameet Bakhai and Dr Waqas Tahir on Thursday 9 December 2021 for a webcast looking at case studies of typical patients that you might see in your practice, and how assessing their cardiovascular risk is central to optimising the care of their type 2 diabetes. The speakers will discuss a series of cases that reflect the challenges and opportunities seen in managing type 2 diabetes, as well as explaining some of the evidence that underpins strategies for improving cardiovascular outcomes in these patients. After the presentation, a live Q&A session offers the opportunity for the speakers to answer questions submitted by the audience.

WHAT DOES THIS PROGRAMME OFFER?

1

2

3

Agenda

An evidence-informed yet person-centred approach to the management of cardiovascular risk in type 2 diabetes

An evidence-informed yet person-centred approach to the management of cardiovascular risk in type 2 diabetes

Live Q&A

Speakers

Dr Shahzada Khan (Chair)

GP Principle, Newham, East London

Dr Waqas Tahir

GPwER in Diabetes, GP Partner, Affinity Care Clayton, and Diabetes Lead, Bradford Care Alliance

Dr Ameet Bakhai

Consultant Cardiologist and Cardiovascular R&D Director, Royal Free London NHS Trust

An evidence-informed yet person-centred approach to the management of cardiovascular risk in type 2 diabetes

This promotional webinar has been developed and funded by Lilly. Lilly products will be discussed at this online event and prescribing information can be found on the platform. OmniaMed Communications has provided editorial, marketing and logistical support. Lilly is a registered trademark of Eli Lilly and Company © 2021 Eli Lilly and Company. All rights reserved.

Prescribing information and adverse event reporting information for Trulicity® (dulaglutide) can be accessed by clicking here
For more information about Trulicity® (dulaglutide) please visit: www.lillydiabetes.co.uk (UK only)

Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.

For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.